IMPACT THERAP-B (07630) surged more than 26% during intraday trading. At the time of writing, the stock was up 20.30% at HK$13.57, with trading turnover reaching HK$149 million.

Starting September 7, IMPACT THERAP-B was added to the Stock Connect list. The company believes that being included in both the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs will help broaden its investor base and potentially enhance trading liquidity for its H-shares.

Additionally, the company's executive director and Chief Executive Officer, Suixiong Cai, recently purchased a total of 100,000 ordinary shares of the company in the open market.

It is worth noting that the company's core product, Senaparib, was approved in January 2025 for first-line maintenance treatment across all ovarian cancer patient populations in China. Beginning January 1, 2026, the drug will be included in the national medical insurance drug catalog. In the first half of the year, China sales revenue reached RMB 70 million, representing a year-on-year increase of 877.8%. This year is expected to mark the acceleration phase of commercial rollout.

The European marketing application for Senaparib has been accepted, with approval expected in the second half of 2026.